All In MedTech

Device Trial Radar · NCT06869122

Bronchoscopic Microwave Ablation of Lung Tissue in Surgical Candidates - UK

Assessment of the Safety and Performance of the AB1 Electrosurgical System for Bronchoscopic Microwave Ablation of Lung Tissue in Surgical Candidates - UK

Last checked: Nov 20, 2026Latest source record: Apr 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

18

Planned (sponsor's estimate)

Start

Jul 14, 2025

Primary completion

Nov 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Creo Medical LimitedNot on our public-company list
Sponsor type
Industry
First posted
Mar 11, 2025

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study involves the use of a medical device, the Creo Medical MicroBlate Flex instrument, to heat and destroy lung tumour cells using microwave energy (this is also called ablation). In this study, the investigators are investigating whether the ablation instrument can be used effectively to treat lung tumours or tumours that have spread to the lungs. If successful, using this technology may mean future patients may not need to undergo surgical removal of these types of lung tumours. The aim of this study is to evaluate the safety and performance of the MicroBlate Flex instrument in treating individuals with cancerous lung tumours that are due to be removed by surgery. All participants in the study will undergo the microwave ablation procedure, which is a separate and additional procedure to their surgical procedure. The study, funded by Creo Medical, will be conducted at sites in the UK and Italy, and will involve up to 18 participants.

Conditions

  • Lung Cancer

Interventions

  • AblationDevice

    Bronchoscopy and microwave ablation of the lung tumour prior to surgical resection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of the MicroBlate Flex AB1 system in lung tumour ablationTime frame: Up to 21 days after the ablation procedure
  2. Technical Success and Performance of the AB1 instrumentTime frame: Up to 28 days post ablation procedure

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Istituto Europeo di Oncologia (IEO), Via Ripamonti 435

    Milan, Italy · Not yet recruiting

  • Royal Brompton and Harefield NHS Foundation Trust, Royal Brompton Hospital, Sydney Street

    London, UK, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.